Elekta AB Class B
EKTAF
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.85B
Close$
$6.07
6.6% downside
Current Fair Value
6.6% downsideOvervalued by 6.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.85 Billion |
|---|---|
| Enterprise Value | $12.73 Billion |
| Dividend Yield | $0.26 (4.94%) |
| Earnings per Share | $-1.38 |
| Beta | 0.95 |
| Outstanding Shares | 383,559,000 |
Return
| Return on Equity | -10.20% |
|---|---|
| Return on Assets | -2.69% |
| Return on Invested Capital | 4.27% |
Valuation & Multiples
| P/E Ratio | -35.85 |
|---|---|
| PEG | -29.18 |
| Price to Sales | 0.15 |
| Price to Book Ratio | 0.36 |
| Enterprise Value to Revenue | 0.76 |
| Enterprise Value to EBIT | 25.2 |
| Enterprise Value to Net Income | -18 |
| Total Debt to Enterprise | 1.1 |
| Debt to Equity | 1.99 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 28, 2026
EPS Estimate
$0.16
Average shareholder expectationRevenue Estimate
$539.90 M
Average shareholder expectationNext Earnings Call
Expected Date
August 27, 2026
EPS Estimate
$0.05
Average shareholder expectationRevenue Estimate
$379.47 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Elekta AB
CEO: Gustaf Salford Elekta AB is a medical technology company. It engages in the provision of clinical solutions for the treatment of cancers and brain disorders. The firm's products and solutions include radiotherapy, stereotactic radiosurgery, oncology in...